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Recent studies have shown that sera from patients with cica-
tricial pemphigoid (CP) contained autoantibodies against 
epidermal antigens of molecular weight 230 kD and/or 
180 kD by immunoblotting, similar to those recognized by 
bullous pemphigoid (BP) sera. Previous immunoprecipita-
tion studies have shown that BP sera only precipitated the 
230-kD antigen. To characterize the CP antigen(s) we tested 
10 CP sera, 10 BP sera, and four controls by both immunopre-
cipitation of radiolabeled cells and immunoblotting of epi-
dermal extracts. For immunoprecipitation, we used 0.5% 
NP-40 extracts of both normal human keratinocytes and 
Pam cells. All CP sera precipitated a 180-kD protein that 
co-migrated with the BP180 antigen precipitated by some 
individual BP sera. Two of these CP sera also faintly bound a 
230-kD protei~ of similar molecular weight as the major 
BP230 antigen. CP and BP sera with an immunoblotting 
pattern of 180 kD immunoprecipitated a co-migrating 180-
kD protein. CP sera reacting by immunoblotting with the 
230-kD antigen precipitated the 180-kD and/or the 230-kD 
antigen. In contrast, BP sera reacting with the 230-k~ 
antigen only precipitated this antigen. In further experI-
ments, labeled 0.5% NP-40 extracts from Pam cells were first 
preabsorbed with a reference BP serum and then immunopre-
cipitated with CP sera. Under these conditions, CP sera t~at 
immunoprecipitated both 180-kD and 230-kD proteins ~lth 
the standard procedure no longer precipitated these protelUS• 
Our results suggest that a 180-kD protein is the major C~ 
target-antigen that demonstrated immunologic cross-reactI-
vities with the BP180 and the BP230 antigens. ] Invest Der-
rnatoI99:174-179,1992 
---------------------------------------------------------------------------------------------------------
C icatricial pemphigoid (CP) is an autoimmune subepi-dermal bullous disease characterized by mucous membrane involvement and scar formation and by in vivo bound immunoglobulins and/or complement along the basement membrane (BMZ) of the epider-
mis and other affected tissues [1,2]. Circulating anti-BMZ autoanti-
bodies can be detected by indirect immunofluorescence (II F) in 
25 - 75% of patients with CP using various substrates [1-4]. Direct 
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Abbreviations: 
BMZ: basement membrane zone 
BP: bullous pemphigoid 
CP: cicatricial pemphigoid 
DE]: dermo-epidermal junction 
DMEM: Oulbecco's modified Eagle's medium 
ELISA: enzyme-linked immuilOsorbent assay 
FITC: fluorescein isothiocyanate 
IIF: indirect immunofluorescence 
NP-40: Nonidet P-40 
PAGE: polyacrylamide gel electrophoresis 
PBS: phosphate-buffered saline 
PV: pemphigus vulgaris 
SOS: sodium dodecyl sulfate 
immunoelectron microscopic studies have demonstrated that cP 
autoantibodies bind in vivo within the dermo-epidermal junctloj
n 
(DE]) to the lower part oflamina lucida and to lamina densa [5- 8 . 
A recent indirect immunoelectron microscopic study has shown 
that CP autoantibodies bind determinants that are localized extrad 
cellularly beneath the hemidesmosomes of basal keratinocytes a~ 
to the adjoining lamina densa within the DE] of normal human sk~ 
[9]. This suggests that CP antigen is different from the 230-k I 
bullous pemphigoid (BP) antigen that is mostly localized intrace -
lularly to the hemidesmosomes of basal keratinocytes [9-14]. , d 
So far, characterization of target-antigen(s) in CP has been carne f 
out by immunochemical means. By immunoblotting of extra~ts 0 
normal human skin, autoantibodies from patients with CP bmd
h
a 
230-240 kD protein [B,15,16] and/or a IBO-kD protein [B] . T d 
molecular weights of these proteins are similar to BP230 an 
BPIBO, the major antigens recognized by BP autoantibodies [15-
21]. Recently, the isolation of partial eDNA clones correspondIng 
to the BP230 and BPIBO antigens and further sequence analYSIS 
have been reported [22- 25]. Such data at the molecular level ar~ 
lacking concerning the nature of target-antigen(s) in CP. The p~ 
pose of the present study was 1) to characterize CP antigen(~) a 
immunoprecipitation using CP autoantibodies, which are restr1~t~_ 
to Ig4 and IgG 1 subclasses [26], and 2) to further study the rela.t1? _ 
ship between CP and BP antigens by sequential immunopreclplta 
tions. 
MATERIALS AND METHODS 
Patients and Sera Sera from 10 patients with CP were,used ~~ 
this study. They have been selected in this study on the baSIS of t 
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Table I. Immunoprecipitation and Western Blot Data of Patients with Cicatricial Pemphigoid (CP) and Bullous Pemphigoid (BP) 
-
CP 
-Patient Westernblot Immunoprecipitation (number) (kD) (kD) 
- 1 230 230 + 180 
2 230 180 
3 230 + 180 230 + 180 
4 230 + 180 180 
5 180 180 
6 180 180 
7 180 180 
8 180 180 9 180 180 10 180 180 
-
presence of circulating anti-BMZ antibodies by IIF among 26 CP 
tatlents prospectively studied in two centers from 1985 to 1990. 
b Irculating anti-BMZ IgG antibodies either by standard IIF [27] or 
r IIF Usmg monoclonal antibodies specific for human IgG sub-
~. asses [26] on normal human skin substrate. Anti-BMZ antibody 
btlls ran~ed from 1/10 to 1/80. All patients had a subepidermal 
u
d 
ous disease with clinical features of CP and deposits of IgG 
an lor C3 along the BMZ of the epidermis by direct immunofluo-
rescence. 
Phtients with CP had clinically a chronic and scarring disease 
: It I a predilection for mucosal involvement (especially oral and 
p cu ar) contrasting with a less important skin involvement [2]. Two 
Batlents had a chronic scarring cutaneous localized form of the 
I ~nstlg-Per')' type [2,28]. Four patients with CP also had linear 
g deposits m addition to IgG and C3 by direct immunofluores-
cence D' . . rd' II c . Irect Immunoelectron microscopy was penorme m a 
i as~s and showed thick and discontinuous immune deposits local-
p~e .on lamina densa and to the lower part of lamina lucida, as 
~hously reported [8]. 
im e Controls included sera of ten patients with typical clinical, 
c rnunologic, and immunoelectron microscopic features ofBP that 
1/~~a1l1ed circulating anti-BMZ IgG antibodies by IIF ranging from 
(PV) to > 1/3200; sera of two patients with pemphigus vul garIS 
cyt t~at contained IgG antibodies that bind cell surface ofkeratmo-
an;s y IIF ranging from 1/50 to 1/200 on normal skin substrate; 
S sera of four healthy subjects. 
_7~~urn samples were obtained at time of diagnosis and stored at 
C until they were analyzed. 
W (S~~tern Irnrnunoblotting Two percent sodium dodecyl sulfate 
ture) protem extracts of normal heat-.separated epidermiS or cul-
ide lormal human keratmocytes subjected to SDS-polyacrylam-
to ge electrophoresis (PAGE) were electrophoretically transferred 
pernltrocellulose and stained by the peroxydase method using a 
StitOlCydase-conjugated anti-human IgG (H+L) goat antibody (In-
[20r Pasteur, Marnes la Coquette, France) as previously reported 
Itt} 
lllUnoprecipitation 
~~~ndard Technique: Pam cells, a mouse epidermal cell line [29]. 
Pam nOrmal human keratinocytes were used in the present study. 
calf cells were grown in RPMI 1640 supplemented with 10% fetal 
afte:erurn. Human keratinocytes from normal human skin obtained 
(D~urgery were grown in Dulbecco's modified Eagle's medium 
ll1.ed· M) supplemented with 10% fetal calf serum or in MCDB 153 
37.~urn: Subconfluent cultures were radiolabeled for 18 to 24 h at 
label tth 50.uCi/ ml of (35S) methionine (Amersham) . The radio-
40) ae d cell layer was then extracted with 0.5% Nonidet P-40 (NP-
sera an d the s~lubilized proteins immunoprecipitated using patient 
La JO~I protem A - bearing staphylococci (Pansorbin, Calbiochem, 
techn0 a, CAl as previously described by Stanley et al [17] . T he 
Ique II1cluded a preabsorption with a normal human serum (or 
BP 
Patient Westernblot Immunoprecipitation 
(number) (kD) (kD) 
11 230 230 
12 230 230 
13 230 230 
14 230 230 
15 230 230 
16 230 230 
17 180 180 
18 180 180 
19 180 180 
20 180 180 
a PV serum in some experiments) prior to the immunoprecipitation 
of protein extracts with the CP or BP sera. Antigen-antibody com-
plexes were eluted from the protein A and dissociated in lOO.u1 of 
gel sample buffer containing 2% SDS and 0.1 M dithiotreitol. The 
resultant proteins were separated by SDS-PAGE on 6% or 7% poly-
acrylamide gels. Gels were f1uorographed and autoradiographed for 
4-10 d at -70°e. Each serum was tested at least twice. 
Sequential Irllltl!tnoprecipitatiorl: In these experiments, 0.5% NP-
40 -labeled extracts were immunoabsorbed using 10 .ul of a CP, BP, 
or PV serum (instead of a normal human serum as in the standard 
procedure) and 100.u1 of 10% (w/v) protein A-bearing staphylo-
cocci (1 h X 2) prior to the immunoprecipitation with CP sera. In 
other experiments, protein extracts were immunoabsorbed using a 
CP serum and protein A prior to the immunoprecipitation with 
control BP sera. Thus, several types of control experiments were 
carried out, including 1) BP-CP; 2) PV-CP; 3) CP-BP; 4) CP-(au-
tologous) CP and CP-(heterologous) CP sequential immunoprecipi-
tations. 
RESULTS 
Western Immunoblotting By immunoblotting from both epi-
dermal and keratinocytes extract~ all sera from patients with either 
CP or BP reacted with either 180-kD or 230-kD antigens. Six CP 
sera specifically reacted with an epidermal antigen of 180-kD, two 
CP sera bound to a 230-kD antigen, and two CP sera recognized 
both the 180-kD and the 230-kD antigens (Table I). Six BP sera 
only recognized the 230-kD antigen and four the 180-kD antigen. 
Immunoprecipitation 
Standard Technique: Results of immunoprecipitation experiments 
(including a pre-clearing with a normal human serum) performed 
with CP sera are summarized in Table 1. Eight CP sera immunopre-
cipitated a 180-kD protein (Fig 1, lanes 2 and 3) of apparently 
identical molecular weight as the 180-kD protein precipitated by 
some BP sera (Fig 1, lane 1). This 180-kD protein was specific for 
these sera because normal human sera did not precipitate this band. 
Two CP sera precipitated both a 180-kD protein and a 230-kD 
protein (Fig 2, lanes 3 and 4). Six BP sera precipitated a similar 
230-kD protein (Fig 2, lal1e 2; Fig 3,lanes 1 and 2). Four BP sera only 
precipitated a 180-kD protein. Similar results were obtained with 
different extracts from either Pam cells or normal human keratino-
cytes . 
Immt~tloprecipitation Pattem Vers.us Western Immunoblotting: CP sera 
reactmg by Immunoblottmg With the 180-kD antigen alone immu-
noprecipitated a similar 180-kD prot~in. On the contrary, a discrep-
ancy between Immunoblottmg and lIumunoprecipitation patterns 
was observed in CP sera reacting by immunoblotting with the 230-
kD antigen. T hese sera precipitated a 180-kD protein either alone 
or associated to the 230-kD protein (Table I). In contrast, immuno-
blotting and immunoprecipitation patterns of the 10 control BP sera 
were identical. Particularly, the four BP sera reacting by immuno-
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Figure 1. 180-kD antigen immunoprecipitated from 0.5% NP-40 extracts 
of cultured keratinocytes. Fluorography of SDS-PAGE-separated, 35S la-
beled immunoprecipitates with BP serum number 17 (lane 1), CP sera 
numbers 6 and 7, respectively (lan es 2 and 3) or normal human serum (lane 
4). Concurrently electrophoresed standards are indicated at right (kD) . A 
protein of 180 kD is specifically precipitated by these CP and BP sera that 
had an immunoblotting pattern of 180 kD. 
blotting with the 180-kD antigen alone immunoprecipitated asimi-
lar 180-kD protein from 0.5% NP-40 protein extracts (Table I). 
Sequential Immunoprecipitations; Labeled 0.5% NP-40 extracts 
from Pam cells were first preabsorbed with either a BP serum with 
an immunoblotting pattern of 230-kD or a normal human serum, 
and then immunoprecipitated with CP sera. Under these condi-
tions, CP sera that immunoprecipitated both 180-kD and (faintly) 
230-kD proteins with the standard procedure (Fig 2, lanes 3 and 4) 
no longer precipitated these proteins (Fig 2, lanes 5 and 6) . On the 
contrary, BP sera still precipitated the 230-kD or the 180-kD pro-
teins when the technique included a pre-clearing with a CP serum 
(data not shown). In another series of experiments, labeled 0.5% 
NP-40 extracts from normal human keratinocytes were first preab-
sorbed with a PV serum, a normal human serum, or a CP serum with 
an immunoblotting pattern of 180 kD and then immunoprecipi-
tated with the same CP serum that were used for preabsorption. 
Under these conditions, the CP serum still precipitates the 180-kD 
230 _ 
180_ 
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• Previous pre-clearing 
with a BP serum 
. . s 
Figure 2. CP sera no longer precipitated the 180-kD and 230-kD prote::o . 
when the extracts were preabsorbed with a BP serum. Immunopreclpltat I 
of 0.5% NP-40 extracts from 35S labeled Pam cells with BP, CP, or norma 
human sera. Lane 1 is a control with normal human serum used for irnrnun~; 
precipitation. Lane 2 shows the immunoprecipitation of the 230-kD ant?~e 
with BP serum number 1. Lanes 3 and 4 show immunoprecipitation 0 t 1 
180-kD and (faintly) of the 230-kD antigens with two CP sera, nurnbe~ a 
and 3, respectively (standard technique including a preabsorption ~It he 
normal human serum). Latles 5 and 6 show immunoprecipitation With ~p 
same CP sera including a pre-clearing of the extract with reference Ie 
serum. Under these conditions CP sera no longer precipitate either t J 
180-kD or the 230-kD antigen. 
antigen after an irrelevant precipitation with a PV serum (data nd: 
shown), and, although faintly, after a previous precipitatIOn ~I t-
the autologous CP serum or a CP serum of identical immuno 0 
ting pattern (Fig 4, l anes 2 and 3). 
DISCUSSION 
r h the In recent years, considerable efforts have been made to estab IS a-
precise nature of the target-antigen(s) recognized by sera fro; hat 
tients with BP. Imrnunochemical studies have demonstrate ~ of 
there were two major BP antigens of apparent molecular welg :115, 
230 kD and 180 kD referred to as BP230 and BP180 antJ~ 'Ie 
respectively [15-21,30,31] . Two BP antigen cDNA clones ;80 
been recently identified corresponding to the BP230 and BP 
VOL. 99, NO. 2 AUGUST 1992 
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Figur 3 11 itn e . Fluorography of SOS-PAGE-separated, 35S labeled Pam ce s, 
nu tnbnoprecipitates with BP sera numbers 11 and 13 (latl es 1 and 2), CP sera 
iliutn ers 5 and 9 (lalles 4 and 5), or normal human serum (lane 3). This figure 
ands~r~tes the typical immunoprecipitation pattern of 230 kO with BP sera 
o kO with CP sera. 
epider 1 . d 1 th rna antigens [22-25]. Northern blots have reveale nat 
Seese two BP antigens are encoded by distinct RNA transcripts [24]. 
BP\~nce analysis has shown a significant homology bet,,:,een 
COn 0 antigen and desmoplakin I and II, whereas BP180 antlgen 
nentatns two collagen domains [25]. Both BP antigens are compo-
d ts of the hemidesmosomes, as demonstrated both by immuno-
ectron . . 1 . 1 pro d microscopic studies [9,12,13,22-24,30] and blOC 1emlca 
Ce ures [32] . . be~n Contrast, the nature of the target antigens involved in CP has 
pre n studied only by means of immunoblotting [B,15,16]. In the 
rna Sent study we have demonstrated that a IBO-kD protein is the \Vi~hrctarget-antigen recognized by autoantibodies from pati~nts 
eYte r By Immunoprecipitation of extracts of cultured keratll1o-
also tal CP sera bound this 180-kD protein. Two of these CP sera 
the atntly bound a 230-kD protein of similar molecular weight as 
PrOtl11a,]or BP230 antigen. None of CP sera pr~cipitates a 120-kD eln . . irnrn ,prevIOusly reported as recognized by some CP sera USll1g 
the Bi~blotting [1 6] . The CP IBO-kD protein co-migrated with 
SO antigen precipitated by some BP sera. As a rule, It has 
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been shown in previous studies that BP sera only precipitated the 
major BP230 antigen [17 ,19]' even when sera had an immunoblot-
ting pattern of IBO kD [31]. With respect to these data, we were 
surprised to find that same pattern of IBO kD by immunoprecipita-
tion for BP sera that reacted with the BPIBO antigen by immuno-
blotting. However, in a recent report, the lS0-kD BP antigen was 
also identified by immunoprecipitation of (14C) keratinocyte ex-
tracts with BP sera [33]. Furthermore, our results concerning the 
immunoprecipitation of the IBO-kD protein with some BP sera 
were confirmed by repeated assays using different extracts from 
normal human keratinocytes cultured in two different conditions or 
from a mouse epidermal cell line (Pam cells). Finally, heterogeneity 
of bullous pemphigoid antigen had been demonstrated even using 
immunoprecipitation of NP-40 extracts of cultured cells derived 
from a squamous cell carcinoma line [34]. 
We found differences between immunoblotting and immunopre-
cipitation 'patterns only in CP sera reacting by immunoblotting 
with the 230-kD antigen, which precipitated a lS0-kD protein 
1 2 
230-
180- ...-
c~ 
3 
.' . _ .... 
'.i'"'~ '" 
c~ c~ 
5 
NHS 
Figure 4. Immunoprecipitation of 0.5% NP-40 extracts from cultured ker-
atinocytes with CP or normal human sera. Fluorography of SOS-PAGE-
separated, 35S-labeled immunoprecipitates with a CP serum number 5 (Iatles 
1 to 3), CP serum number 3 (latle 4) or normal human serum (latle 5). 
Labeled extracts were first preabsorbed with a normal human serum (la/les 1, 
4, and 5), CP serum number 5 (la/Ie 2), and CP serum number 8 (latle3) . This 
figure shows that small but significant amounts of 180-kO CP antigen are 
left after a previous pre-clearing with CP sera with an immunoblotting 
pattern of 180 kO (/atles 2 and 3). 
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either alone or associated with the 230-kD protein. The discrep-
ancies between these and previous results do not reflect major dif-
ferences in techniques because we have used the same well-estab-
lished immunoprecipitation procedure [17] used in other studies 
[19,30,31]. However, our results indicate that lS0-kD and 230-kD 
proteins precipitated by CP sera have a molecular weight similar to 
that of the BP1S0 and BP230 antigens, respectively. Although it is 
established that the BPlS0 antigen is not a degradation product of 
the BP230 antigen [30,35,36], immunologic cross-reactivities be-
tween the BP230 and BP1S0 antigens have recently been demon-
strated using affinity-purified antibodies against these antigens and 
immunoprecipitation technique [30]. The results of sequential im-
munoprecipitations ofNP-40 protein extracts with successively BP 
and CP sera indicate immunologic cross-reactivities in addition to 
similar molecular weight. Unfortunately, we were not able to dem-
onstrate the converse, i.e., that BP sera no longer precipitated the 
230-kD or the lS0-kD proteins when the technique included a 
pre-clearing with a CP serum. This is probably due to low amounts 
of CP antibodies (titer of anti-BMZ antibodies in CP sera ofl/l0 by 
IIF, compared with 1/S00 to 1/3200 for BP sera) that might have 
been insufficient to precipitate all BP antigen in the first step of 
these experiments. This was suggested by the result of a CP-CP 
sequential immunoprecipitation that showed that some CP antigen 
can be left after a first immunoprecipitation (Fig 4). 
That the lS0-kD antigen that is recognized by a majority of CP 
sera by both immunoblotting and immunoprecipitation techniques 
is similar to the BPlS0 antigen that is detected by approximately 
one third ofBP sera has several implications. Indirect immunoelec-
tron microscopic studies performed either with affinity-purified 
antibodies [30] or with rabbit antiserum prepared against the lyso-
genic BPlS0 fusion protein [24] have shown that BPlS0 antigen is a 
component of the epidermal hemidesmosome. However, an extra-
cellular localization of a part of the BPlS0 antigen was suggested by 
a recent study of binding of sera to intact or permeabilized SCaBER 
cells in an enzyme-linked immunabsorbent assay [ELISA] [31]. This 
contrasts with the exclusively intracellular localization of the 
BP230 antigen [9,31,37]. Because studies of the fine localization of 
the BP1S0 antigen within the hemidesmosome are lacking to date, 
it cannot be excluded that the BPlS0 antigen has an extracellular 
domain. We have recently shown by indirect immunoelectron mi-
croscopy that CP antigen has an extracellular localization in front of 
the hemidesmosome in the lamina lucida and over the upper part of 
lamina densa [9]. Thus it is possible that CP autoantibodies either 1) 
predominantly recognize an extracellular epitope of the BP lS0 
antigen, that could at least partly conciliate immunochemical and 
ultrastructural data; or 2) bind a lS0-kD protein which could be a 
component of anchoring filaments, distinct from the BP ISO anti-
gen, although of similar molecular weight. 
We 1V0uid like to tlrank Jean-Louis Prelld'llOmme for Iris sliggestioflS cOtrcenrirrg the 
imltllHloprecipitation teclltlique alld Miss Michele Pistellr for the photographs. 
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